Here, we discuss how to improve adherence to endocrine therapy in women with HR-positive breast cancer, as well as the side effects and the reasons for discontinuation.
Julia P. Brockway, MD
Advertisement
Articles by Julia P. Brockway, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Afami-cel in Metastatic Synovial Sarcoma
2
EC Approves Encorafenib/Cetuximab/FOLFOX in 1L BRAF V600E–Mutant mCRC
3
The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word
4
Binimetinib Tablets Receive Tentative FDA Approval in Melanoma/NSCLC
5